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Effects of NADPH oxidase inhibitor in diabetic nephropathy.
Background. We used apocynin to test the hypothesis that su-
peroxide anion (O−2 ) from nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase underlies the development of di-
abetic nephropathy in the rat.
Methods. Rats received apocynin (16 mg/kg/day) from
2 to 8 weeks after inducing diabetes mellitus (DM) with
streptozotocin.
Results. DM increased excretion of hydrogen peroxide
(H2O2), lipid peroxidation products (LPO), nitric oxide prod-
ucts (NOx), and protein. The kidneys of rats with DM had in-
creased expression of p47phox and gp91phox and endothelial
nitric oxide synthase (eNOS), and increased mesangial matrix
with expression of fibronectin and collagen I. Apocynin pre-
vented the increase in excretion of H2O2, LPO, and protein in
diabetic rats, increased renal NOx generation, and prevented
the increased renal expression of gp91phox and the mem-
brane fraction of p47phox, and reverted the mesangial matrix
expansion.
Conclusion. Activation of NADPH oxidase with transloca-
tion of p47phox to the membrane underlies the oxidative stress
and limited NO generation, despite enhanced eNOS expression
in a model of diabetic nephropathy. Apocynin prevents these
changes and the associated proteinuria.
The balance between the production of reactive oxy-
gen species (ROS), notably superoxide anion (O−2 ) and
hydrogen peroxide (H2O2), and the antioxidant defense
system that includes superoxide dismutase (SOD) and
peroxidases, determines the degree of oxidative stress.
An increased production and/or decreased metabolism
of ROS have been implicated in the pathogenesis of re-
nal injury in diabetes mellitus (DM) [1, 2].
An important source of ROS production is nicoti-
namide adenine dinucleotide phosphate (NADPH)
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oxidase. This enzyme generates O−2 during the respiratory
burst in phagocytes. The phagocyte NADPH oxidase
consists of membrane-bound subunits (gp91phox and
p22phox) and cytosolic subunits (p47phox, p40phox,
p67phox, and Rac) [3]. When activated, p47phox is phos-
phorylated, and the cytosolic components translocate to
the membrane, where they form a molecular cluster of
the catalytically active oxidase. The mechanism is some-
what different in other cells. For example, NADPH ox-
idase is assembled primarily on intracellular organelles
in endothelial cells [4]. Moreover, there are homologues
of the gp91phox subunit that include Nox1, which is ex-
pressed in vascular smooth muscle cells (VSMCs), and
Nox4, which is expressed in the kidney and blood ves-
sels [5]. In the kidney, NADPH oxidase components
are expressed abundantly in the renal vessels and in
the glomerular mesangial and podocyte cells, the macula
densa, and the thick ascending limb, distal tubule, and col-
lecting ducts [6]. The renal expression of NADPH oxidase
is enhanced in rat diabetic nephropathy. In this model,
an angiotensin-converting enzyme inhibitor (ACEI) or
an angiotensin receptor blocker (ARB) suppresses renal
NADPH oxidase, renal ROS generation, and microalbu-
minuria [2]. Thus, we tested the hypothesis that admin-
istration of the NADPH oxidase inhibitor, apocynin, to
diabetic rats will reduce renal O−2 production and prevent
proteinuria.
Apocynin is a methoxy-substituted catechol from the
medicinal herb Picroria kurroa. It inhibits NADPH oxi-
dase by impeding the assembly of p47phox and p67phox
subunits within the membrane NADPH oxidase complex
[7, 8]. Administration of apocynin to rats with collagen-
induced arthritis prevents joint destruction [9]. Likewise,
apocynin administration to a rat model of Crohn’s dis-
ease reduces small intestinal inflammation [10]. It has also
been proposed as a therapeutic agent for atherosclerotic
disease [8], but its effect in diabetic nephropathy has not
been studied.
We evaluated the effect of apocynin on NADPH ox-
idase expression and examined its effect on ROS gen-
eration and proteinuria in a rat model of insulinopenic
diabetic nephropathy.
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METHODS
Animal preparation
Female Sprague-Dawley rats weighing 180 to 250 g
were housed in cages and fed standard pellet diet (Na+
content 0.21 g/100 g) and tap water ad libitum. Diabetes
was induced by a single tail vein injection of streptozo-
tocin (STZ, 60 mg/kg body weight; Sigma Chemical Co.,
St. Louis, MO, USA) diluted in citrate buffer, pH 4.5.
Two weeks later, the diabetic rats were randomly
divided into 2 groups matched for body weight and
blood glucose: DM group without treatment (DM, N =
12) and DM given apocynin (DM + apocynin, N =
12) composed of rats treated with apocynin (16 mg/kg/
day in drinking water; Avocado Research Chemicals,
Heysham, England). This dose of apocynin (4-hydroxy-
3-methoxyacetophenone) was based on in vivo studies of
prolonged dosing in which apocynin (4 to 100 mg/kg/day)
prevented NADPH oxidase activation, vascular super-
oxide (O−2 ) production and remodeling, hypertension,
inflammation, and/or organ dysfunction in a number of
models of chronic oxidative stress [10–15]. Since a daily
dose of 100 mg/kg was no more effective than 15 mg/kg in
preventing neuropathy and reduced nerve blood flow in
diabetic rats [12], a dose of 16 mg/kg was selected for this
study. Age-matched rats without STZ injection served
as controls (N = 12). Twenty-four–hour urine was col-
lected using metabolic cages at 4 and 8 weeks after STZ
injection.
At these time points, 6 animals from each group were
anesthetized with pentobarbital (50 mg/kg body weight,
IP). The abdominal aorta was cannulated, and mean
blood pressure (MBP) was measured by a pressure trans-
ducer (Nihon Koden, Tokyo, Japan). Blood was collected,
and the kidneys were perfused retrogradely with ice-cold
phosphate-buffered saline (PBS). The right kidney was
removed and cut into half for Western blotting (N =
6), cryosection (N = 3), or glomerular isolation (N =
3). The left kidney was perfused with periodate-lysine-
paraformaldehyde (PLP) solution. Kidney slices for
immunohistochemical analysis were immersed in PLP so-
lution overnight at 4◦C and embedded in wax (polyethy-
lene glycol 400 distearate; Polysciences, Inc., Warrington,
PA, USA).
Measurement of lipid peroxidation, H2O2, nitrite, crea-
tinine, protein, and glucose
The lipid peroxidation products in urine were mea-
sured by the thiobarbituric acid method [16]. Samples
(100 lL) were mixed with 100 lL of 8% sodium dode-
cyl sulfate (SDS), 400 lL of 20% acetic acid at pH 3.5,
and 400 lL of 0.8% 4,6-dihydroxy-2-mercaptopyrimidine
(2-thiobarbituric acid, TBA; Wako Pure Chemical
Industries, Ltd., Osaka, Japan). After a 60-minute in-
cubation at 95◦C, the malondialdehyde (MDA) formed
was measured by fluorophotometry (Hitachi F-2000,
Tokyo, Japan) with excitation/emission wavelengths of
515/553 nm.
Production of peroxides, including H2O2 and perox-
ynitrite, was measured in urine and isolated glomeruli
obtained by graded sieving using the 2′,7′-dichlorodi-
hydrofluorescein-diacetate (DCFH-DA) method, as de-
scribed previously [17]. Briefly, samples were incubated
with DCFH-DA (16 lg/mL final concentration; Molec-
ular Probes, Eugene, OR, USA) for 20 minutes at 37◦C.
DCFH-DA is oxidized by peroxides to the highly fluores-
cent compound, 2′,7′-dichlorofluorescein (DCF), which
was measured with a spectrofluorometer using excita-
tion/emission wavelengths of 485/535 nm [18].
Nitrite production in kidney homogenates was mea-
sured by the Griess method. Protein was precipitated by
adding equal volumes of 0.3N NaOH and 5% ZnSO4.
The supernatants were incubated with Griess solution,
and nitrite was measured with a spectrophotometer at
540 nm [19]. To confirm the specificity of DCF signal for
hydrogen peroxide production, isolated glomeruli from
DM rat were preincubated with 5000 U/mL of catalase
(Wako) for 20 minutes, and then incubated with DCFH-
DA reagent with catalase for another 20 minutes.
Urine protein was measured by the Bradford method
(Bio-Rad, Hercules, CA, USA), and corrected by urinary
creatinine as described previously [2]. Blood glucose was
measured by Glutest E II (Kyoto Daiichi Kagaku, Kyoto,
Japan). HbA1c was measured with the DCA 2000 plus
system (Bayer Medical, Tokyo, Japan).
Western blotting
As described in detail previously [20], the right kid-
ney was removed immediately after perfusion with
PBS and homogenized in 4 mL of ice-cold buffer
containing 20 mmol/L Tris, at pH 7.2, 0.5 mmol/L
ethylenediaminetetraacetic acid (EDTA), 0.5 mmol/L
ethylene glycol-bis (b-aminoethyl ether)-N,N,N′,N′-
tetraacetic acid (EGTA), 20 lmol/L leupeptin, 10 mmol/L
dithiothreitol, 0.1 mmol/L phenylmethylsulfonyl fluoride.
Homogenates were centrifuged at 5000g for 15 minutes
at 4◦C. The supernatants were centrifuged at 48,000g for
60 minutes at 4◦C to isolate cytosolic and membrane frac-
tions. The resulting supernatant was removed (cytosol
fraction), and the pellet was resuspended in buffer con-
taining 20 mmol/L Tris-HCl, pH 7.5, 1 mmol/L EDTA,
and 250 mmol/L sucrose (membrane fraction) [21].
Samples were diluted in an equal volume of SDS sam-
ple buffer. Aliquots (25 lg of protein/lane) were applied
to 4 to 20% polyacrylamide gradient gels (Daiichi Pure
Chemicals Co., Tokyo, Japan) and electrophoresed, fol-
lowed by electroblotting on to nitrocellulose membranes.
The membranes were blocked for 30 minutes with 5%
nonfat dried milk in Tris-buffered saline containing 0.1%
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Tween 20 (TBST), followed by overnight incubation with
monoclonal antibodies recognizing p47phox, gp91phox,
and p22phox [6] at 1:1000 dilutions, and a polyclonal
antibody recognizing endothelial nitric oxide synthase
(eNOS; Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA) at a 1:100 dilution. After washing with TBST,
membranes were incubated for 4 hours with horseradish
peroxidase (HRP)-conjugated antimouse IgG or antirab-
bit IgG secondary antibodies (1:1000 dilutions; Dako,
Glostrup, Denmark) to detect p47phox, gp91phox, and
p22phox or eNOS, respectively. Blots were washed again
with TBST, followed by developing solution containing
0.8 mmol/L diaminobenzidine (DAB; Dojindo Labora-
tories, Kumamoto, Japan), 0.01% H2O2, and 3 mmol/L
NiCl2. The density of the bands was analyzed using NIH
Image software.
Immunohistochemistry
Kidney slices were processed for immunohistochem-
istry using the labeled streptavidin biotin method, as
described previously [20]. Wax sections (2 lm) were de-
waxed, incubated first with 3% H2O2 for 10 minutes to
eliminate endogenous peroxidase activity, and thereafter
with blocking serum for 15 minutes. They were incu-
bated overnight with polyclonal antibodies recognizing
p47phox, gp91phox [6], and eNOS (Santa Cruz Biotech-
nology), type I collagen, and fibronectin (Chemicon
International, Inc., Temecula, CA, USA) at 1:100 dilu-
tions. The sections were rinsed with TBST and incubated
for 1 hour with biotinylated antirabbit IgG secondary an-
tibody at a 1:400 dilution. After rinsing with TBST, the
sections were incubated for 1 hour with HRP-conjugated
streptavidin solution (Dako). HRP labeling was detected
using a peroxide substrate solution containing 0.8 mmol/L
DAB and 0.01% H2O2. The sections were counterstained
with hematoxylin before being examined under a light
microscope.
NO production detected by NADPH diaphorase histo-
chemistry and DAF-2
Kidneys were embedded in OCT compound and
frozen. Cryosections (5 lm) were cut, rinsed in PBS,
and incubated with 1 mmol/L reduced b-NADPH (Sigma
Chemical Co.), 0.2 mmol/L nitro blue tetrazolium
(Wako), and 0.2% Triton X-100 for 40 minutes at 37◦C.
Sections were rinsed with 0.1 mol/L Tris-HCl buffer, and
photographed under a light microscope [22].
Cryosections were incubated with 10 lmol/L
diaminofluorescein-2 diacetate (DAF-2 DA, Daiichi
Pure Chemicals Co.) for 1 hour. This probe is converted
covalently to a fluorescent compound on interaction with
NO. It has been validated as a measure of NO activity
in isolated vasa recta [18, 23]. The NO production was
detected using a fluorescence microscope with excita-
tion/emission wavelengths of 495/515 nm. To confirm the
specificity of NO production, samples from DM rats were
preincubated with 1 mmol/L Nx-nitro-L-arginine methyl
ester (L-NAME, Sigma Chemical Co.) for 60 minutes,
and then NADPH diaphorase or DAF-2DA reagents
were added with 1 mmol/L L-NAME.
Morphologic study
Wax sections (2 lm) were stained with periodic acid–
Schiff (PAS) for light microscopic morphologic study. The
degree of mesangial matrix expansion was assessed by an
experienced observer who was blinded as to the sample
origin, using a semiquantitative scoring method: grade
0, normal glomeruli; grade 1, mesangial expansion area
up to 25% (minimal); grade 2, 25% to 50% (moderate);
grade 3, 50% to 75% (moderate-severe); grade 4, 75% to
100% (severe). The glomerular matrix expansion index
(GMI) was calculated as the average of 100 glomeruli in
each kidney slice [24, 25]. The data were assessed from
5 rats in each group.
Statistical analysis
All data are expressed as mean ± SE. The mean val-
ues were compared among the 3 groups using analysis
of variance (ANOVA), followed, where appropriate, by
Fisher protected least significant difference test. Proba-




As shown in Table 1, blood glucose and HbA1c were
significantly higher in diabetic rats than in controls. Di-
abetic rats administered apocynin had higher values for
HbA1c compared to those with DM at 4 weeks, but there
was no difference at 8 weeks. Mean blood pressure was
comparable between DM and control, but it was reduced
by apocynin at 4 and 8 weeks.
Expression of NADPH oxidase subunits
The p47phox component of NADPH oxidase was ex-
pressed in glomerular cells and distal tubules in kidneys
of control rats. Its expression was enhanced in kidneys
of DM rats, especially in the podocytes. Apocynin treat-
ment reduced p47phox staining in diabetic rats (Fig. 1).
Western blotting confirmed that p47phox protein was
increased significantly in DM rats at 8 weeks in both
membrane and cytosolic fractions of the kidney [mem-
brane fraction: 0.33 ± 0.04 vs. 0.20 ± 0.03 arbitrary units
(au), P < 0.05; cytosolic fraction: 0.29 ± 0.03 vs. 0.18 ±
0.03 au, P < 0.05, Fig. 2]. Apocynin significantly reduced
p47phox expression in the membrane fractions of the
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Table 1. Physiologic data
Control DM DM + apocynin
(4 week, N = 12) (4 week, N = 12) (4 week, N = 12)
(8 week, N = 6) (8 week, N = 6) (8 week, N = 6)
Body weight g 281 ± 7 245 ± 8b 233 ± 11c
323 ± 10 288 ± 16 276 ± 18a
Blood glucose mg/dL 141 ± 6 437 ± 38c 491 ± 37c
175 ± 12 365 ± 27c 407 ± 24c
HbA1c% 2.63 ± 0.04 7.03 ± 0.55c 8.38 ± 0.24c,d
2.75 ± 0.10 9.30 ± 0.63c 8.80 ± 0.45c
Mean blood pressure mm Hg 99 ± 6 84 ± 7 77 ± 4a
99 ± 6 89 ± 5 79 ± 6a
Urinary LPO nmol/mg Cr 7.8 ± 1.0 44.2 ± 5.4c 39.7 ± 3.8c
6.5 ± 0.7 98.1 ± 7.6c 66.0 ± 10.7c,d
Urinary H2O2 FI unit/mg Cr 7.2 ± 0.4 11.4 ± 1.0c 7.4 ± 0.6f
11.4 ± 1.2 26.9 ± 6.3a 10.1 ± 1.3e
Urinary protein mg/mg Cr 0.37 ± 0.03 0.61 ± 0.07b 0.42 ± 0.03d
0.31 ± 0.03 0.55 ± 0.13a 0.27 ± 0.02d
aP < 0.05, bP < 0.01, cP < 0.001 vs. control; dP < 0.05, eP < 0.01, fP < 0.001 vs. DM.
kidney (0.21 ± 0.03, P < 0.05 vs. DM, Fig. 2) but not
in the cytosolic fraction (0.25 ± 0.02, NS vs. DM, Fig. 2).
The ratio of p47phox expression in membranes:cytosol
was 1.10 ± 0.07 in control rats. This ratio was unchanged
in DM rats (1.13 ± 0.05), but was reduced significantly in
DM rats given apocynin (0.85 ± 0.06; P < 0.05 vs. DM or
vs. control). This indicates that apocynin inhibited mem-
brane translocation of p47phox.
The gp91phox was expressed in glomerular cells and
distal tubules. Its expression was enhanced in DM rats at
8 weeks. Apocynin reduced the expression of gp91phox
in the glomeruli (Fig. 1). Western blot analysis of the
membrane fraction of the kidney showed a specific band
for gp91phox that was increased in DM rats (0.30 ±
0.02 vs. 0.20 ± 0.02 au, P < 0.01, Fig. 3). Apocynin pre-
vented the significant increase in the membrane fraction
of gp91phox protein expression of DM rats (0.25 ± 0.02,
NS vs. control, Fig. 3).
The expression of p22phox in the membrane fraction
was unchanged in DM rats compared to control (0.27 ±
0.01 vs. 0.24 ± 0.01 au, NS, Fig. 3), and was not modified
by apocynin (0.24 ± 0.01, NS vs. DM, Fig. 3).
Glomerular and urinary oxidative products
Associated with the increased NADPH oxidase com-
ponents in DM rats, their isolated glomeruli showed
increased peroxide production, which was reduced by
apocynin treatment (Fig. 4). The DCF signal in the
glomerulus from DM rat was reduced by catalase pre-
treatment, indicating that the signals represent hydro-
gen peroxide production. Renal excretion of LPO was
increased in DM rats at both 4 and 8 weeks. This was
reduced at 8 weeks by apocynin. Renal excretion of per-
oxide was increased in DM rats, and was reduced by apoc-
ynin at both 4 and 8 weeks (Table 1).
Expression of eNOS and nitrite production in the kidney
Immunohistochemical analysis showed that the ex-
pression of eNOS in endothelial cells of the renal artery
was increased in DM rats (Fig. 1), confirming our previous
study [2]. Western blot analysis confirmed an increase in
eNOS expression in DM rats (0.28 ± 0.01 vs. 0.19 ± 0.01
au, P < 0.001, Fig. 5). Treatment with apocynin did not
change eNOS expression in DM rats (0.32 ± 0.01, NS vs.
DM, Fig. 5).
NADPH diaphorase histochemistry was used as a de-
scriptive method to detect NOS expression [22, 26, 27],
and DAF-2 fluorescence to detect NO activity [18, 23].
These methods indicated that NO production from NOS
in proximal tubules and endothelial cells of the renal
vasculature was increased in DM rats, and that was
suppressed by L-NAME. NO production was increased
further by apocynin treatment (Fig. 6). NO production,
assessed quantitatively by NOx generated in the kidney
homogenates, was increased in DM rats (71.0 ± 4.7 vs.
32.2 ± 3.0 lmol/mL, P < 0.01, Fig. 7) and increased fur-
ther by apocynin (100.2 ± 11.6, P < 0.05 vs. DM, Fig. 7).
Urinary protein excretion
Urinary protein excretion was increased in DM rats.
Apocynin reduced urinary protein excretion at 4 and
8 weeks (Table 1).
Mesangial matrix expansion
DM rats had increased mesangial matrix expansion
(GMI: 1.36 ± 0.16 vs. 0.27 ± 0.05, P < 0.001, Fig. 1), which
was ameliorated by apocynin (0.38 ± 0.03, P < 0.001
vs. DM, Fig. 1). Immunohistochemistry demonstrated in-
creased mesangial expression of fibronectin and type I
collagen in DM rat mesangial cells. Apocynin suppressed
these changes (Fig. 1).
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Control DM DM + Apocynin
Fig. 1. Light micrographs illustrating immunostaining for NADPH oxidase p47phox (A to C) and gp91phox (D to F) in the kidney, immunostaining
for eNOS in the renal artery (G to I), periodic acid–Schiff (PAS)-stained sections of the kidney (J to L), and immunostaining for fibronectin (M to
O) and type I collagen (P to R). Control (A, D, G, J, M, and P), DM rat at 8 weeks (B, E, H, K, N, and Q), and DM rat treated with apocynin (C, F,
I, L, O, and R). Each bar indicates 50 lm. Magnification, (A to C) ×240, (J to R) ×300, (D to F) ×360, and (G to I) ×400.


























Fig. 2. Western blot analysis of NADPH oxi-
dase p47phox in membrane and cytosolic frac-
tions at 8 weeks. The band at the molecular
weight of 47 kD was quantified by densitom-
etry from 6 rats in each group. ∗P < 0.05 vs.
























Fig. 3. Western blot analysis of NADPH oxi-
dase gp91phox and p22phox in the membrane
fraction at 8 weeks. The band at the molecular
weight of 91 kD and 22 kD was quantified by
densitometry from 6 rats in each group. ∗∗P <
0.01 vs. control.
Fig. 4. Peroxide production in isolated glomeruli. Control (A), DM rat at 8 weeks (B), DM rat treated with apocynin (C), and an isolated glomerulus



















Fig. 5. Western blot analysis of eNOS in whole kidney homogenate at
8 weeks. The band at the molecular weight of 133 kD was quantified by
densitometry from 6 rats in each group. ∗∗∗P < 0.001 vs. control.
DISCUSSION
The main new findings of this study are that blockade
of NADPH oxidase with apocynin in diabetic rats pre-
vents the membrane translocation of p47phox and the
increased expression of gp91phox in the kidney, and pre-
vents oxidative stress, proteinuria, and glomerulopathy,
while enhancing NO generation. These effects are inde-
pendent of changes in blood sugar, but are accompanied
by a reduction in blood pressure.
The activity of NADPH oxidase is regulated both by
expression of the subunits and by phosphorylation of
p47phox following stimulation by agents such as an-
giotensin II, IL-1b , and TNF-a [28–30]. We showed by
Western blotting and immunohistochemistry that the re-
nal expression of p47phox and gp91phox were enhanced
in diabetic rats. This is consistent with recent reports that
p47phox and gp91phox are up-regulated in the kidneys
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Fig. 6. NO production detected by NADPH diaphorase histochemistry (A to D) and DAF-2 (E to H). Control (A, E), DM rat at 8 weeks (B, F),
DM rat treated with apocynin (C, G), and DM rat pretreated with 1 mmol/L L-NAME (D, H). Representative pictures from 3 rats in each group.

















Fig. 7. Nitrite production in whole kidney homogenate at 8 weeks.
∗∗P < 0.01, ∗∗∗P < 0.001 vs. control; +P < 0.05 vs. DM.
of salt loaded rats [31] since hyperglycemic rats have
an expanded extracellular fluid volume. Apocynin re-
duced the expression of p47phox in the membrane, but
not in the cytosolic fraction, indicating that it inhibited
translocation of the p47phox subunit to the membrane
fraction. The expression of another membrane-bound
subunit, gp91phox, was increased in the kidney of DM
rats, and this increase also was prevented by apocynin.
Another critical membrane subunit, p22phox, did not
change significantly with diabetes, and was not altered
by apocynin. Thus, a mechanism of NADPH oxidase
inhibition by apocynin may be suppression of translo-
cation of the cytosolic p47phox component to the mem-
brane fraction, with associated suppression of its anchor,
gp91phox, where it forms a molecular cluster to activate
NADPH oxidase. It is not clear from this study whether
this represents translocation to the cell membrane, or
to associated intracellular organelles that would also be
separated with the membrane components. These effects
of apocynin in the kidney are consistent with its known
actions. Apocynin, after cellular uptake and peroxida-
tion, prevents serine phosphorylation of p47phox, and
blocks its association with gp91phox. This blunts NADPH
oxidase activation, as shown in studies of neutrophils
[32] and angiotensin II (Ang II)-stimulated VSMCs from
human resistance arteries [33]. Apocynin is excreted in
active form through the kidneys [34]. Apocynin pretreat-
ment prevents the generation of oxidative stress in the
heart [35] and diaphragm [15] after lipopolysaccharide,
in the lung after ischemia-reperfusion [36], in the in-
testine after iodoacetamide treatment [10], in arteries
after endothelial injury [13], and in the blood vessels
after mineralocorticoid/salt-induced hypertension [11,
14]. While the primary established target for apocynin
is to block assembly and activation of NADPH oxidase,
there are secondary consequences of this in endothelial
cells where xanthine oxidase expression and O−2 genera-
tion from this enzyme also is inhibited [37].
NO generation in the kidneys, as assessed in this study
by NOx generation by kidney tissue, is increased in early
streptozotocin-induced DM [38]. Increased NO has been
assigned a key role in the accompanying glomerular hy-
perfiltration [38–40] and prevention of hypertension [41].
Increased NO has been ascribed both to an increased ex-
pression of eNOS [2, 38, 40], which was confirmed in this
study, and to activation of neuronal NOS expressed in
the macula densa [40]. Fluorescent NO-sensitive dye and
diaphorase histochemical methods were used to locate
the source of NOS and the activity of NO in this study.
They located increased NO in renal proximal tubule cells
and vascular endothelial cells in the DM rats. While
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apocynin did not further modify eNOS expression, it en-
hanced renal NOx generation, and enhanced NO bioac-
tivity, as assessed from DAF-2 fluorescence in vascular
endothelial cells. This indicates that apocynin reduced
NO bioinactivation by O−2 in diabetes. It may have pro-
tected eNOS from the effects of oxidation of tetrahydro-
biopterin, which can uncouple eNOS from NO synthesis
and perpetuate O−2 generation [42–45]. This is consistent
with the enhanced renal nitrotyrosine deposition in the
kidneys in this DM model, which implies an enhanced
interaction of O−2 with NO [2].
Proteinuria in DM is considered to have both a
hemodynamic (glomerular capillary hypertension and
hyperfiltration) and a structural/cellular basis (alter-
ations in basement membrane, mesangial cell matrix,
and podocyte function) [38]. As in a previous study, dia-
betic rats developed modest proteinuria by 4 weeks [2],
but this was prevented by apocynin. Apocynin has an
organ-protective effect in models of rheumatoid arthritis,
inflammatory bowel disease, ischemic reperfusion lung
injury, and sepsis [9, 10, 15, 36, 46], where it inhibits the
neutrophil oxidative burst and generation of cytokines,
including TNF-a, IL-1b , IFN-c, IL-4, and IL-10 [9, 36,
46]. The mechanism of the antiproteinuric effect of apoc-
ynin is not clear. Apocynin did prevent the DM-induced
increases in renal expression of gp91phox, membrane-
associated p47phox, H2O2 excretion, glomerular mesan-
gial expansion, and mesangial expression of fibronectin
and collagen I and expression of p47phox in podocytes,
and of H2O2 generation by isolated glomeruli. Apocynin
may have prevented deterioration in glomerular mesan-
gial function or in glomerular protein permeability in
DM. For example, preventing activation of p47phox in
podocytes may limit local oxidative stress. While this re-
mains conjectural, oxidative stress is known to impair the
integrity of tight junctions between cells [47]. Our data
are not a direct evidence of correlation between protein-
uria and H2O2 excretion, and apocynin prevented the
increase in protein excretion of DM rats at both 4 and
8 weeks, yet reduced (and did not prevent) the increase
in LPO excretion only at 8 weeks. However, the relation-
ship between H2O2 generation in glomeruli and LPO or
H2O2 excretion in the urine is presently unclear.
To our knowledge, this is the first report of an ef-
fect of apocynin to limit proteinuria and development
of glomerulopathy in early diabetic nephropathy. While
it requires further study to determine its exact mecha-
nism of action, it extends previous studies of the actions
of apocynin in diabetes or hyperglycemia. Thus, apocynin
blocks the effect of increased glucose concentration to ac-
tivate protein kinase C (PKC)-induced NADPH oxidase,
and fibronectin secretion by peritoneal cells [48] to cause
endothelial dysfunction in isolated vessels [49], and to
impair contractility in cardiac myocytes [50]. Apocynin
blocks the increase in PKC, O−2 generation and prolifer-
ation during incubation of mesangial cells with glycated
albumin [51]. Administration of apocynin to rats with DM
reduces vascular O−2 (assessed by electron paramagnetic
resonance [52]), and prevents diabetic neuropathy and re-
duced nerve blood flow [12]. Apocynin protects against
atherosclerosis in several models [8]. Therefore, apoc-
ynin could have benefits beyond prevention of diabetic
nephropathy.
CONCLUSION
Activation of NADPH oxidase in a model of diabetic
nephropathy with translocation of p47phox to the mem-
brane underlies the generation of peroxides and lim-
its NO generation. Apocynin effectively prevents these
changes, and prevents the associated proteinuria and
glomerular matrix expansion.
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